Teduglutide vs Glepaglutide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicTeduglutideGlepaglutide
What it is

An analogue of human GLP-2 that binds GLP-2 receptors in the intestine, according to the label.1

A modified GLP-2 analogue with several amino-acid substitutions and a C-terminal hexa-lysine, recorded as glepaglutide in FDA’s substance registry.3

FDA status

FDA-approved

FDA-approved as Gattex for short bowel syndrome1,2

FDA-approved. Drugs@FDA lists Gattex with an original approval date of December 21, 2012. The cited label has no boxed warning.1,2

Is teduglutide FDA-approved?

In clinical trials

In clinical trials; not FDA-approved3,4

Not FDA-approved. None of the sources reviewed here reports an approval of glepaglutide.3,4

Is glepaglutide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.5

Not among the six peptides the policy lists.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Glepaglutide is not among them.5,6

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list glepaglutide.7

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial Study 1 (NCT00798967): a randomized, double-blind, placebo-controlled trial in 86 adults with short bowel syndrome dependent on parenteral support, described in the label.1
  • Small, short, or incompletely reported human study Study 2 (NCT00930644): a two-year open-label extension of Study 1 in 88 adults, described in the label.1

Smaller controlled human trials

  • Controlled human trial A randomized, double-blind, placebo-controlled Phase 3 trial (NCT03690206) in 106 patients with short bowel syndrome and intestinal failure, lasting 24 weeks (2025).4
Records collected

30 ClinicalTrials.gov records and 24 PubMed records collected

8 ClinicalTrials.gov records and 1 PubMed record collected

Area of study

Gut and digestion1

Gut and digestion4

Latest dated events
  1. DailyMed publishes the Gattex label version cited on this page.1
  2. FDA approves Gattex, according to Drugs@FDA.2
  1. The Phase 3 trial of glepaglutide in 106 patients with short bowel syndrome is published.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    GATTEX (teduglutide) kit · SPL version 20 · published 2025-09-18 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: GATTEX (teduglutide), NDA 203441 · original approval December 21, 2012 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Glepaglutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  4. 4
    Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial (2025) · PMID 39708985 ↗

    Gastroenterology · Official source · Source checked November 15, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026